- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax ; volume:636 ; number:8041 ; day:30 ; month:10 ; year:2024 ; pages:241-250 ; date:12.2024
Nature; 636, Heft 8041 (30.10.2024), 241-250, 12.2024
- Klassifikation
-
Biowissenschaften, Biologie
- Urheber
-
Sango, Junya
Carcamo, Saul
Sirenko, Maria
Maiti, Abhishek
Mansour, Hager
Ulukaya, Gulay
Tomalin, Lewis E.
Cruz-Rodriguez, Nataly
Wang, Tiansu
Olszewska, Malgorzata
Olivier, Emmanuel
Jaud, Manon
Nadorp, Bettina
Kroger, Benjamin
Hu, Feng
Silverman, Lewis
Chung, Stephen S.
Wagenblast, Elvin
Chaligne, Ronan
Eisfeld, Ann-Kathrin
Demircioglu, Deniz
Landau, Dan A.
Lito, Piro
Papaemmanuil, Elli
DiNardo, Courtney D.
Hasson, Dan
Konopleva, Marina
Papapetrou, Eirini P.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41586-024-08137-x
- URN
-
urn:nbn:de:101:1-2502182126448.275646512497
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sango, Junya
- Carcamo, Saul
- Sirenko, Maria
- Maiti, Abhishek
- Mansour, Hager
- Ulukaya, Gulay
- Tomalin, Lewis E.
- Cruz-Rodriguez, Nataly
- Wang, Tiansu
- Olszewska, Malgorzata
- Olivier, Emmanuel
- Jaud, Manon
- Nadorp, Bettina
- Kroger, Benjamin
- Hu, Feng
- Silverman, Lewis
- Chung, Stephen S.
- Wagenblast, Elvin
- Chaligne, Ronan
- Eisfeld, Ann-Kathrin
- Demircioglu, Deniz
- Landau, Dan A.
- Lito, Piro
- Papaemmanuil, Elli
- DiNardo, Courtney D.
- Hasson, Dan
- Konopleva, Marina
- Papapetrou, Eirini P.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia
Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
Funktionelle Charakterisierung von RAS-Mutanten im Rhabdomyosarkom
Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression
Correction to: Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia
The effects of mutant Ras proteins on the cell signalome
XBP1 promotes NRASG12D pre-B acute lymphoblastic leukaemia through IL-7 receptor signalling and provides a therapeutic vulnerability for oncogenic RAS RAS
Structure-based inhibitor design of mutant RAS proteins—a paradigm shift
Dependence of NPPS creates a targetable vulnerability in RAS-mutant cancers
Tetracycline-inducible RNAi knockdown of SCL (stem cell leukaemia) in mice
Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia
Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
Funktionelle Charakterisierung von RAS-Mutanten im Rhabdomyosarkom
Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression
Correction to: Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia
The effects of mutant Ras proteins on the cell signalome
XBP1 promotes NRASG12D pre-B acute lymphoblastic leukaemia through IL-7 receptor signalling and provides a therapeutic vulnerability for oncogenic RAS RAS
Structure-based inhibitor design of mutant RAS proteins—a paradigm shift
Dependence of NPPS creates a targetable vulnerability in RAS-mutant cancers
Tetracycline-inducible RNAi knockdown of SCL (stem cell leukaemia) in mice
Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia
Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
Funktionelle Charakterisierung von RAS-Mutanten im Rhabdomyosarkom
Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression
Correction to: Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia
The effects of mutant Ras proteins on the cell signalome
XBP1 promotes NRASG12D pre-B acute lymphoblastic leukaemia through IL-7 receptor signalling and provides a therapeutic vulnerability for oncogenic RAS RAS
Structure-based inhibitor design of mutant RAS proteins—a paradigm shift
Dependence of NPPS creates a targetable vulnerability in RAS-mutant cancers